Full Press Release Details
Lexicon Reveals "INTO THE DARK" Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following Hospitalization.
LXRX
Lexicon Reveals "INTO THE DARK" Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following Hospitalization
Key Takeaway: Lexicon Reveals "INTO THE DARK" Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following Hospitalization
Price reaction · baseline $2.68 (2023-03-03 close) · hit after-hours · clean, no other LXRX news in the window
day 0 close
-3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus